{"url_path":"/sec/crvo/8-k/2026-06-09/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **         **Submission of Matters to a Vote of Security Holders**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-09","source_url":"https://www.sec.gov/Archives/edgar/data/1053691/0001437749-26-019909-index.html","accession_number":"0001437749-26-019909","cik":"0001053691","ticker":"CRVO","issuer_name":"CervoMed Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1053691/0001437749-26-019909-index.html","primary_entity_key":"0001053691","primary_entity_name":"CervoMed Inc."},"word_count":572,"has_tables":true,"body_markdown":"**Item 5.07**         **Submission of Matters to a Vote of Security Holders**\n\n \n\nThe 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of CervoMed Inc. (the “Company” or “we”) was held on June 8, 2026. Stockholders of record at the close of business on April 17, 2026 (the “Record Date”), were entitled to vote at the Annual Meeting and, as of the Record Date, there were 9,258,719 shares of the Company’s common stock outstanding. At the Annual Meeting, the holders of 6,218,593 shares were present, virtually or by proxy, representing approximately 67.2% of the shares outstanding as of the Record Date and, accordingly, a quorum was present at the Annual Meeting.\n\n \n\nThe matters submitted to the Company’s stockholders and voted upon at the meeting, which are more fully described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2026 (the “Proxy Statement”), as well as the results of each such vote were as follows:\n\n \n\n \n(1)\n\nProposal No. 1 – To elect eight persons to serve as directors until the Company’s next Annual Meeting of Stockholders or until their respective successors are elected and qualified.\n\n \n\nThe election of each nominee pursuant to Proposal No. 1 required the affirmative vote of a plurality of the votes present and entitled to vote at the Annual Meeting and, accordingly, each nominee received the requisite number of votes for election at the Annual Meeting.\n\n \n\n​\n\n​\n\nFor\n\n​\n\n​\n\nWithheld\n\n​\n\n​\n\nBroker Non-Votes\n\n​\n\nJohn Alam, MD\n\n​\n\n3,155,846\n\n​\n\n​\n\n29,174\n\n​\n\n​\n\n3,033,573\n\n​\n\nJoshua S. Boger, PhD\n\n​\n\n3,141,298\n\n​\n\n​\n\n43,722\n\n​\n\n​\n\n3,033,573\n\n​\n\nSylvie Grégoire, PharmD\n\n​\n\n3,153,199\n\n​\n\n​\n\n31,821\n\n​\n\n​\n\n3,033,573\n\n​\n\nJane H. Hollingsworth, JD\n\n​\n\n3,126,987\n\n​\n\n​\n\n58,033\n\n​\n\n​\n\n3,033,573\n\n​\n\nJeffrey V. Poulton\n\n​\n\n3,154,178\n\n​\n\n​\n\n30,842\n\n​\n\n​\n\n3,033,573\n\n​\n\nDavid Quigley\n\n​\n\n3,153,944\n\n​\n\n​\n\n31,076\n\n​\n\n​\n\n3,033,573\n\n​\n\nMarwan Sabbagh, MD\n\n​\n\n3,154,321\n\n​\n\n​\n\n30,699\n\n​\n\n​\n\n3,033,573\n\n​\n\nFrank Zavrl\n\n​\n\n3,153,967\n\n​\n\n​\n\n31,053\n\n​\n\n​\n\n3,033,573\n\n​\n\n \n\n \n(2)\n\nProposal No. 2 – To ratify the selection of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.\n\n \n\nThe approval of Proposal No. 2 required the affirmative vote of a majority of the votes present and entitled to vote at the Annual Meeting and, accordingly, Proposal No. 2 received the requisite number of votes for approval at the Annual Meeting.\n\n \n\nFor\n\nAgainst\n\nAbstain\n\n6,092,751\n\n21,433\n\n104,409\n\n \n\n \n(3)\n\nProposal No. 3 – To approve, on an advisory basis, the compensation of the Company’s named executive officers during the year ended December 31, 2024, as disclosed in the Proxy Statement.\n\n \n\nThe approval of Proposal No. 3 required the affirmative vote of a majority of the votes present and entitled to vote at the Annual Meeting and, accordingly, Proposal No. 3 received the requisite number of votes for approval at the Annual Meeting.\n\n \n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n3,073,013\n\n104,221\n\n7,786\n\n3,033,573\n\n \n\n \n(4)\n\nProposal No. 4 – To approve Amendment No. 1 to the CervoMed Inc. 2025 Equity Incentive Plan.\n\n \n\nThe approval of Proposal No. 4 required the affirmative vote of a majority of the votes present and entitled to vote at the Annual Meeting and, accordingly, Proposal No. 4 received the requisite number of votes for approval at the Annual Meeting.\n\n \n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n3,044,744\n\n132,860\n\n7,416\n\n3,033,573"}